HIV-2 integrase variation in integrase inhibitor-naïve adults in Senegal, West Africa.
Antiretroviral therapy for HIV-2 infection is hampered by intrinsic resistance to many of the drugs used to treat HIV-1. Limited studies suggest that the integrase inhibitors (INIs) raltegravir and elvitegravir have potent activity against HIV-2 in culture and in infected patients. There is a paucit...
Main Authors: | Geoffrey S Gottlieb, Robert A Smith, Ndeye Mery Dia Badiane, Selly Ba, Stephen E Hawes, Macoumba Toure, Alison K Starling, Fatou Traore, Fatima Sall, Stephen L Cherne, Joshua Stern, Kim G Wong, Paul Lu, Moon Kim, Dana N Raugi, Airin Lam, James I Mullins, Nancy B Kiviat, Papa Salif Sow for the UW-Dakar HIV-2 Study Group |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2011-01-01
|
Series: | PLoS ONE |
Online Access: | http://europepmc.org/articles/PMC3134476?pdf=render |
Similar Items
-
Integrase and integration: biochemical activities of HIV-1 integrase
by: Deprez Eric, et al.
Published: (2008-12-01) -
Resistance to Integrase Inhibitors
by: Mathieu Métifiot, et al.
Published: (2010-06-01) -
Relationship between HIV integrase polymorphisms and integrase inhibitor susceptibility: An in silico analysis
by: Hotma Martogi Lorensi Hutapea, et al.
Published: (2018-12-01) -
Prototype Foamy Virus Integrase Displays Unique Biochemical Activities among Retroviral Integrases
by: Anthony J. Rabe, et al.
Published: (2021-12-01) -
HIV-1 integrase tetramers are the antiviral target of pyridine-based allosteric integrase inhibitors
by: Pratibha C Koneru, et al.
Published: (2019-05-01)